GlaxoSmithKline-Medicago's COVID-19 Vaccine Candidate Elicit Strong Immune Response

Interim Phase 2 trial results of GlaxoSmithKline plc GSK and its collaborating partner Medicago Inc’s COVID-19 vaccine candidate showed protective antibody levels ten times higher than in patients who have recovered from the disease.
The vaccine generated similar immune responses in all age groups with no serious safety events in the mid-stage trial.
Medicago’s vaccine candidate with GSK’s pandemic adjuvant exhibited an acceptable safety profile, and adverse events were primarily mild or moderate and of transient duration.
The Phase 3 portion, which started in March this year, is evaluating the efficacy and safety of the CoVLP formulation, compared to placebo, in up to 30,000 participants.
According to Nathalie Charland, Medicago’s senior director of scientific and medical affairs, the companies aim to collect efficacy data this summer and apply for authorization later this year, reports Bloomberg.
Yesterday, GSK and Sanofi SA SNY reported “strong immune responses” in early tests of their COVID-19 vaccine.
Price Action: GSK shares are down 0.6% at $39.36 during the premarket session on the last check Tuesday.